Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of actinic keratoses with Birken Oleogel versus cryotherapy and combination therapy
2004-003917-17Phase 2Completed
- Sponsor
- Birken AG
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Birch bark extract in actinic keratosis (AK) (3 arms), sponsored by Birken AG. Primary endpoint: Regression of actinic keratoses at 12 weeks. Started Jun 2005; status: completed.
02
Drugs
Birch bark extract
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2004-003917-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003917-17.